Drug intelligence / Profile preview

BPI-9302A

Development stage: Preclinical
Lead developer: Beta Pharma
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

BPI-9302A is an investigational antibody-drug conjugate (ADC) being developed by Beta Pharma for the treatment of solid tumors. As an ADC, it is designed to leverage the specificity of a monoclonal antibody to deliver a potent cytotoxic payload directly to cancer cells expressing a specific target antigen, thereby enhancing efficacy while reducing systemic side effects. BPI-9302A is part of a broader suite of ADC candidates in Beta Pharma's pipeline, which includes BPI-9303A, BPI-9304A, and BPI-9305A. While the specific molecular target and payload for BPI-9302A have not been publicly disclosed, it represents the company's expansion into complex biologics for oncology.

Beyond the preview

Go deeper on BPI-9302A.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BPI-9302A.

Explore the full profile